You are here

Prices & Quotes - UK Markets - Sensyne Health (SENS)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Up 18.25p
Change Today:
3.00p
Market Cap:
30.08m
Sector:
Medical Equipment and Services

Sensyne signs five-year patient data deal with Cambridge NHS trust

By Josh White

Date: Friday 03 Dec 2021

LONDON (ShareCast) - (Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health has signed a five-year, non-exclusive strategic research agreement with Cambridge University Hospitals NHS Foundation Trust, it announced on Friday.
The AIM-traded firm said the deal would enable the "ethical application" of clinical AI research, by analysing de-identified patient records to carry out research.

It said the partnership would cover research across the trust's areas of disease expertise and specialism in cancer, cardiovascular disease and rare diseases.

Cancer research would be a key focus of the partnership, with Sensyne saying it would use its expertise to analyse cancer patient pathways to reduce patient waiting times and improve patient care.

Additionally, under the agreement, Sensyne and the NHS trust would focus on clinical decision tools to support patient care, by developing new AI-enabled software to help clinicians analyse complex data to improve clinical decision making.

They would also use AI to analyse retrospective clinical data, and generate synthetic control arms to support clinical trials more effectively, accelerating the process of drug development for patients.

Finally, the deal would allow for a focus on drug discovery, by helping to discover new medicines aimed at treating rare and common diseases, including cardiovascular disease and cancers.

The company said the dataset covered three million unique patient records, with around one million patient contacts per year from a patient population of about five million people.

It said the new agreement took the number of Sensyne's strategic research deals with NHS Trusts and US health systems to 16, and brought the combined total of de-identified patient data directly accessible for medical research to 25.5 million patients, made up of 12.1million in the UK and 13.4 million in the United States.

"Sensyne is delighted to be working with Cambridge University Hospitals NHS Foundation Trust, a leading national centre for the treatment of rare or complex conditions and a university teaching hospital with a worldwide reputation," said Sensyne Health chief executive officer Paul Drayson.

"Cambridge University Hospitals is also recognised as a leader in the use of digital tools and health data to improve patient care and has built a large, high quality data set as a result."

Lord Drayson said the trust had "invested heavily" in its digital infrastructure and the curation of its data, meaning Sensyne could start work immediately.

"Together we aim to use the power of ethical AI to make a real difference in finding new and better ways to treat cancer and other complex diseases."

At 1416 GMT, shares in Sensyne Health were flat at 90p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Sensyne Health Market Data

Currency UK Pounds
Price 18.25p
Change Today 3.00p
52 Week High 185.00p
52 Week Low 14.50p
Volume 10,209,235
Shares Issued 164.80m
Market Cap 30.08m
Beta 0.15

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Price Trend
market
  1. empty market
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. empty sector
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. half sector star
Price Chg 6m
market
  1. empty market
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. empty sector
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. half sector star
  3. empty sector
  4. empty sector
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector

Sensyne Health Dividends

No dividends found

Trades for 26-Jan-2022

Time Volume / Share Price
13:14 3,341 @ 18.50p
13:13 3,989 @ 18.50p
13:13 5,335 @ 18.50p
12:55 25,000 @ 18.43p
12:55 5,340 @ 18.50p

Sensyne Health Key Personnel

CEO Paul Drayson